Format

Send to

Choose Destination
Stem Cells Transl Med. 2015 Sep;4(9):1028-32. doi: 10.5966/sctm.2015-0054. Epub 2015 Jul 1.

Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Author information

1
Institute of Immunobiology, St. Gallen, Switzerland; Tyrolean Cancer Research Institute, Innsbruck, Austria; Internal Medicine V and Maximilian.Boesch@kssg.ch.
2
Department of Gynecology and Obstetrics, Medical University Innsbruck, Innsbruck, Austria.
3
Internal Medicine I, Klinikum der Barmherzigen Schwestern Linz, Linz, Austria;
4
Internal Medicine V and.
5
Tyrolean Cancer Research Institute, Innsbruck, Austria; Internal Medicine V and.
6
Tyrolean Cancer Research Institute, Innsbruck, Austria; Internal Medicine V and Medical Clinic III, Oncology, Hematology and Rheumatology, University Clinic Bonn, Bonn, Germany.

Abstract

Ionophore antibiotics were reported to selectively kill cancer stem cells and to overcome multidrug resistance, but mechanistic studies of the significance of drug transporters for treatment with these compounds are lacking. We applied chemosensitivity testing of well-characterized human cancer cell lines to elaborate on whether drug transporters are involved in protection from the cytotoxic effects of the ionophore antibiotics salinomycin and nigericin. Our experiments demonstrated that ionophore antibiotics were ineffective against both stem-like ovarian cancer side population cells (expressing either ABCB1 or ABCG2) and K562/Dox-H1 cells, which constitute a genetically defined model system for ABCB1 expression. Considering that cancer stem cells often express high levels of drug transporters, we deduced from our results that ionophore antibiotics are less suited to cancer stem cell-targeted treatment than previously thought.

SIGNIFICANCE:

Ionophore antibiotics such as salinomycin have repeatedly been shown to target cancer stem and progenitor cells from various tumor entities. Meanwhile, cancer stem cell (CSC)-selective toxicity of ionophore antibiotics seems to be a commonly accepted concept that is about to encourage their clinical testing. This study provides data that challenge the concept of targeted elimination of CSC by ionophore antibiotics. Stem-like ovarian cancer side population (SP) cells expressing high levels of ABC drug transporters are shown to largely resist the cytotoxic effects of salinomycin and nigericin. Furthermore, using a small interfering RNA-based knockdown model specific for ABCB1, this study demonstrates that ABC drug transporters are indeed causally involved in mediating protection from ionophore antibiotics. Considering that it is a hallmark of CSCs to exhibit drug resistance conferred by ABC drug transporters, it must be deduced from these results that CSCs may also be protected from ionophore antibiotics by means of drug-transporter mediated efflux.

KEYWORDS:

Cancer stem cell; Drug transporter; Ionophore antibiotic; Nigericin; Salinomycin

PMID:
26136502
PMCID:
PMC4542876
DOI:
10.5966/sctm.2015-0054
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center